Filter By:

Binimetinib and Encorafenib

07/06/2019

ESMO World GI Congress

BEACON CRC: A Randomized, 3-Arm, Phase 3 Study of Encorafenib and Cetuximab With or Without Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer

S. Kopetz, et al.

Binimetinib and Encorafenib

06/03/2019

2019 ASCO Annual Meeting

Update on Overall Survival in COLUMBUS: A Randomized Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in Patients With BRAF V600–Mutant Melanoma

G. Liszkay, et al

Binimetinib and Encorafenib

03/20/2019

Journal of Clinical Oncology

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-in Results from the Phase III BEACON Colorectal Cancer Study

E. Van Cutsem, et al.

Binimetinib and Encorafenib

01/19/2019

2019 Gastrointestinal Cancers Symposium (ASCO GI)

Updated Results of the BEACON Colorectal Cancer (CRC) Safety Lead-In: Encorafenib (ENCO) + Binimetinib (BINI) + Cetuximab (CETUX) for BRAF V600E‒Mutant CRC

S. Kopetz, et al.

Binimetinib and Encorafenib

10/24/2018

2018 Society for Melanoma Research (SMR) Annual Congress

Characteristics of Pyrexia With Encorafenib (ENCO) Plus Binimetinib (BINI) in Patients With BRAF-Mutant Melanoma

M. Mandala, et al.

Binimetinib and Encorafenib

09/12/2018

The Lancet Oncology

Overall Survival in Patients With BRAF-Mutant Melanoma Receiving Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib (COLUMBUS): a Multicentre, Open-Label, Randomised Phase 3 Trial

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

06/23/2018

ESMO World Congress on Gastrointestinal Cancer

BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti–Epidermal Growth Factor Receptor Antibody Cetuximab for BRAFV600E Metastatic Colorectal Cancer

E. Van Cutsem, M.D., et al.

Binimetinib and Encorafenib

06/04/2018

ASCO Annual Meeting

Adverse Events of Special Interest in the Phase 3 COLUMBUS Study

Helen J. Gogas, M.D., et al.

Binimetinib and Encorafenib

06/04/2018

ASCO Annual Meeting

Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

R. Dummer, M.D., et al.

Binimetinib and Encorafenib

03/21/2018

The Lancet Oncology

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

R. Dummer, M.D., et al.